Drug Approval | November 10, 2024
Granules India’s Unit V facility secures USFDA EIR with NAI status
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
